Dr Helen Marshall

PhD

Department of Infection, Immunity and Cardiovascular Disease

Research Staff Scientist

Helen Marshall
Helen Marshall
H.Marshall@sheffield.ac.uk
+44 114 215 9145

Full contact details

Dr Helen Marshall
Department of Infection, Immunity and Cardiovascular Disease
Polaris
18 Claremont Crescent
Sheffield
S10 2TA
Profile

I have worked on the development and application of hyperpolarised gas and proton lung MRI at the University of Sheffield since 2009.  Previously I was a post-doctoral fellow at the University of Toronto working on dynamic contrast-enhanced breast imaging.  I have a PhD in MRI Physics and a BSc in Physics from Imperial College London.

Research interests

My research interests are focused on the application of MR imaging techniques in patients with lung disease.  Projects that I have worked on include:

  • early detection of lung disease in children with cystic fibrosis
  • visualisation of collateral and delayed ventilation in patients with advanced chronic obstructive pulmonary disease (COPD)
  • imaging of ventilation response to therapies in patients with asthma and COPD
  • visualisation of ventilation and perfusion matching in patients with chronic thromboembolic pulmonary hypertension, asthma and COPD
  • imaging ventilation and microstructural changes in young adults with congenital diaphragmatic hernia

I am involved in clinical research study design and delivery, devising MR acquisition protocols and image computing workflows, and performing data analysis and interpretation. I helped to establish and am active in maintaining our clinical hyperpolarised gas lung imaging service.

Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

Other

Current projects
  • Imaging a large cohort of patients with asthma and/or COPD with 129Xe MRI as a sub-study of the NOVELTY study.
  • Comparison of hyperpolarised gas and free-breathing proton ventilation MRI in patients with cystic fibrosis.
  • Imaging the effects of mepolizumab in patients with COPD.